{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:28:19Z","timestamp":1771460899262,"version":"3.50.1"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"39","license":[{"start":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T00:00:00Z","timestamp":1600992000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Medical Science Foundation of Zhejiang Health Bureau","award":["No.2006A016, No.2005B012,"],"award-info":[{"award-number":["No.2006A016, No.2005B012,"]}]},{"name":"Medical Science Foundation of Zhejiang Health Bureau","award":["2009B026"],"award-info":[{"award-number":["2009B026"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81502646"],"award-info":[{"award-number":["81502646"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81502647"],"award-info":[{"award-number":["81502647"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>For patients with locoregionally advanced nasopharyngeal carcinoma (NPC), induction chemotherapy (IC) regimens based on TPF (docetaxel, cisplatin, and 5-fluorouracil), TP (docetaxel and cisplatin), and GP (gemcitabine and cisplatin) have shown excellent survival outcomes as the first-line therapy; however, no trials comparing the efficacy and safety of TPF, TP, and GP have been reported. We report 2 phase II trials comparing the treatment outcomes and side effects of 3 different IC regimens followed by concurrent chemoradiotherapy in locoregionally advanced patients with NPC.<\/jats:p>\n            <jats:p>A total of 206 locoregionally advanced patients with NPC treated with a combination treatment from January 2012 to January 2014 were enrolled in the 2 studies. The patients received TPF-, TP-, and GP-based IC regimens every 3 weeks, followed by intensity-modulated radiotherapy and concurrent therapy with cisplatin every 3 weeks.<\/jats:p>\n            <jats:p>After a median follow-up duration of 47 months (10\u201360 months), the 3-year local recurrence-free survival, regional recurrence-free survival, distant metastases-free survival, progression-free survival, and overall survival rates were 96.4%, 100%, 87.7%, 86%, and 94.7% in the TPF arm; 91.7%, 95.9%, 91.9%, 85.2%, and 92% in the TP arm; 98.6%, 100%, 89.0%, 87.6%, and 89.2% in the GP arm. The survival differences among the 3 arms were not statistically significant (<jats:italic toggle=\"yes\">P<\/jats:italic> &gt; .05). The multivariate analysis demonstrated that the IC regimen was not an independent prognostic factor for any survival outcomes. The patients in the TP arm experienced significantly lower grade 3\/4 toxicities than the patients in the other 2 arms.<\/jats:p>\n            <jats:p>TP-based IC regimen has similar efficacy compared with TPF- and GP-based IC regimens; however, TP-based IC regimen has a lower toxicity profile.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000022283","type":"journal-article","created":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T18:10:41Z","timestamp":1600971041000},"page":"e22283","source":"Crossref","is-referenced-by-count":12,"title":["Optimal induction chemotherapeutic regimen followed by concurrent chemotherapy plus intensity-modulated radiotherapy as first-line therapy for locoregionally advanced nasopharyngeal carcinoma"],"prefix":"10.1097","volume":"99","author":[{"given":"Fangzheng","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Cancer Hospital of University of Chinese Academy of Sciences"},{"name":"Department of Radiation Oncology, Zhejiang Cancer Hospital"},{"name":"Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences"},{"name":"Zhejiang Key Laboratory of Radiation Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiang","family":"Chuner","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Cancer Hospital of University of Chinese Academy of Sciences"},{"name":"Department of Breast Tumor Surgery, Zhejiang Cancer Hospital, Zhejiang Hangzhou"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Cancer Hospital of University of Chinese Academy of Sciences"},{"name":"Department of Radiation Oncology, Zhejiang Cancer Hospital"},{"name":"Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences"},{"name":"Zhejiang Key Laboratory of Radiation Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Fengqin","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Cancer Hospital of University of Chinese Academy of Sciences"},{"name":"Department of Radiation Oncology, Zhejiang Cancer Hospital"},{"name":"Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences"},{"name":"Zhejiang Key Laboratory of Radiation Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Zhimin","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Cancer Hospital of University of Chinese Academy of Sciences"},{"name":"Department of Radiation Oncology, Zhejiang Cancer Hospital"},{"name":"Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences"},{"name":"Zhejiang Key Laboratory of Radiation Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun","family":"Quanquan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Cancer Hospital of University of Chinese Academy of Sciences"},{"name":"Department of Radiation Oncology, Zhejiang Cancer Hospital"},{"name":"Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences"},{"name":"Zhejiang Key Laboratory of Radiation Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liu","family":"Tongxin","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Cancer Hospital of University of Chinese Academy of Sciences"},{"name":"Department of Radiation Oncology, Zhejiang Cancer Hospital"},{"name":"Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences"},{"name":"Zhejiang Key Laboratory of Radiation Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fu","family":"Zhenfu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Cancer Hospital of University of Chinese Academy of Sciences"},{"name":"Department of Radiation Oncology, Zhejiang Cancer Hospital"},{"name":"Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences"},{"name":"Zhejiang Key Laboratory of Radiation Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiang","family":"Yangming","sequence":"additional","affiliation":[{"name":"Department of Digital Earth, Institute of Remote Sensing and Digital Earth, CAS, Beijing, People's Republic of China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,9,25]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.canlet.2016.01.040","article-title":"Global trends in incidence and mortality of nasopharyngeal carcinoma","volume":"374","author":"Tang","year":"2016","journal-title":"Cancer Lett"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.oraloncology.2015.08.005","article-title":"Intensity-modulated radiation therapy versus 2D-RT or 3D-RT for the treatment of nasopharyngeal carcinoma: a systematic review and meta-analysis","volume":"51","author":"Zhang","year":"2015","journal-title":"Oral Oncol"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1200\/JCO.2008.19.9109","article-title":"Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: Radiation Therapy Oncology Group phase II trail 0225","volume":"27","author":"Lee","year":"2009","journal-title":"J Clin Oncol"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.oraloncology.2012.03.022","article-title":"The strength\/weakness of the AJCC\/UICC staging system (7th edition) for nasopharyngeal carcinoma and suggestions for future improvement","volume":"48","author":"Lee","year":"2012","journal-title":"Oral Oncol"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.radonc.2011.10.009","article-title":"The seventh edition of the UICC\/AJCC staging system for nasopharyngeal carcinoma is prognostically useful for patients treated with intensity-modulated radiotherapy from an endemic area in China","volume":"104","author":"Chen","year":"2012","journal-title":"Radiother Oncol"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.ijrobp.2008.07.062","article-title":"Re-evaluation of 6th edition of AJCC staging system for nasopharyngeal carcinoma and proposed improvement based on magnetic resonance imaging","volume":"73","author":"Mao","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1470-2045(11)70320-5","article-title":"Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial","volume":"13","author":"Chen","year":"2012","journal-title":"Lancet Oncol"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0360-3016(96)80007-1","article-title":"Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV(> or=N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival","volume":"35","author":"Cvitkovic","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1002\/(SICI)1097-0142(19981201)83:11<2270::AID-CNCR6>3.0.CO;2-T","article-title":"Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Asian-Oceanian Clinical Oncology Association Nasopharynx Cancer Study Group","volume":"83","author":"Chua","year":"1998","journal-title":"Cancer"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1200\/JCO.2001.19.5.1350","article-title":"Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma","volume":"19","author":"Ma","year":"2001","journal-title":"J Clin Oncol"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1002\/cncr.10473","article-title":"A prospective, randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in patients with advanced nasopharyngeal carcinoma","volume":"94","author":"Hareyama","year":"2002","journal-title":"Cancer"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa071028","article-title":"Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer","volume":"357","author":"Vermorken","year":"2007","journal-title":"N Engl J Med"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa070956","article-title":"Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer","volume":"357","author":"Posner","year":"2007","journal-title":"N Engl J Med"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1093\/jnci\/djp007","article-title":"Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation","volume":"101","author":"Pointreau","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/S1470-2045(16)30410-7","article-title":"Induction chemotherapy plus concurrent chemotherapy versus concurrent chemoradiotheray alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomized controlled trial","volume":"12","author":"Sun","year":"2016","journal-title":"Lancet Oncol"},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2008.18.1545","article-title":"Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma","volume":"27","author":"Hui","year":"2009","journal-title":"J Clin Oncol"},{"key":"R18-20230915","doi-asserted-by":"crossref","first-page":"91150","DOI":"10.18632\/oncotarget.20017","article-title":"Addition of 5-fluorouracil to first-line induction chemotherapy with docetaxel and cisplatin before concurrent chemoradiotherapy does not improve survival in locoregionally advanced nasopharyngeal carcinoma","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"R19-20230915","first-page":"521","article-title":"Synergistic interaction between cisplatin and gemcitabine in vitro","volume":"2","author":"Bergman","year":"1996","journal-title":"Clin Cancer Res"},{"key":"R20-20230915","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/S0140-6736(16)31388-5","article-title":"Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial","volume":"388","author":"Zhang","year":"2016","journal-title":"Lancet"},{"key":"R21-20230915","first-page":"781","article-title":"Is gemcitabine and cisplatin induction chemotherapy superior in locoregionally advanced nasopharyngeal carcinoma?","volume":"31","author":"Zheng","year":"2015","journal-title":"Pak J Med Sci"},{"key":"R22-20230915","doi-asserted-by":"crossref","first-page":"6763","DOI":"10.18632\/oncotarget.14279","article-title":"Induction chemotherapy for the treatment of non-endemic locally advanced nasopharyngeal carcinoma","volume":"8","author":"Zhao","year":"2017","journal-title":"Oncotarget"},{"key":"R23-20230915","first-page":"96798","article-title":"Gemcitabine\/cisplatin induction chemotherapy before concurrent chemotherapy and intensity-modulated radiotherapy improves outcomes for locoregionally advanced nasopharyngeal carcinoma","volume":"8","author":"Wang","year":"2007","journal-title":"Oncotarget"},{"key":"R24-20230915","first-page":"39756","article-title":"Outcome and long-term efficacy of four facio-cervical fields conformal radiotherapy for nasopharyngeal carcinoma","volume":"8","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"R25-20230915","doi-asserted-by":"crossref","first-page":"75544","DOI":"10.18632\/oncotarget.17357","article-title":"Efficacy and safety of nimotuzumab with neoadjuvant chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"R26-20230915","first-page":"94127","article-title":"Association of the neoadjuvant chemotherapy cycle with survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma: a propensity-matched analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"R27-20230915","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3727\/096504017X15079846743590","article-title":"Long-term use of nimotuzumab in combination with intensity-modulated radiotherapy and chemotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma: experience of a single institution","volume":"26","author":"Wang","year":"2018","journal-title":"Oncol Res"},{"key":"R28-20230915","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/cncr.30566","article-title":"Effects of induction docetaxel, platinum, and fluorouracil chemotherapy in patients with stage III or IVA\/B nasopharyngeal cancer treated with concurrent chemoradiation therapy: final results of 2 parallel phase clinical trial","volume":"124","author":"Kong","year":"2017","journal-title":"Cancer"},{"key":"R29-20230915","first-page":"46","article-title":"Neo-adjuvant docetaxel and cisplatin followed by concurrent cisplatin with radiation therapy in treatment of locally advanced nasopharyngeal carcinoma","volume":"10","author":"Hassan","year":"2008","journal-title":"Gulf J Oncolog"},{"key":"R30-20230915","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00280-013-2157-2","article-title":"Phase II trial of neoadjuvant docetaxel and cisplatin followed by intensity-modulated radiotherapy with concurrent cisplatin in locally advanced nasopharyngeal carcinoma","volume":"71","author":"Zhong","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"R31-20230915","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.ijrobp.2006.06.016","article-title":"Treatment of stage IV(A-B) nasopharyngeal carcinoma by induction-concurrent chemoradiotherapy and accelerated fractionation: impact of chemotherapy schemes","volume":"66","author":"Yau","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R32-20230915","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s00405-011-1720-x","article-title":"Experience with combination of cisplatin plus gemcitabine chemotherapy and intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma","volume":"269","author":"He","year":"2012","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"R33-20230915","doi-asserted-by":"crossref","first-page":"899","DOI":"10.7314\/APJCP.2014.15.2.899","article-title":"Gemcitabine and Cisplatin followed by chemo-radiation for advanced nasopharyngeal carcinoma","volume":"15","author":"Jamshed","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"R34-20230915","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00280-009-1152-0","article-title":"Phase II study of docetaxel, cisplatin, and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal cancer","volume":"65","author":"Bae","year":"2010","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000022283","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T01:40:05Z","timestamp":1694828405000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000022283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,25]]},"references-count":33,"journal-issue":{"issue":"39","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000022283","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,25]]}}}